Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Income from Continuing Operations (2017 - 2025)

VYNE Therapeutics' Income from Continuing Operations history spans 9 years, with the latest figure at 5747000.0 for Q2 2025.

  • For Q2 2025, Income from Continuing Operations rose 38.83% year-over-year to 5747000.0; the TTM value through Jun 2025 reached 38521000.0, down 38.27%, while the annual FY2025 figure was 26736000.0, 32.84% up from the prior year.
  • Income from Continuing Operations reached 5747000.0 in Q2 2025 per VYNE's latest filing, up from 8603000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5612000.0 in Q1 2023 to a low of 14276000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 8899111.11, with a median of 8648500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 93.62% in 2021, then plummeted 100.25% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 8372000.0 in 2021, then rose by 7.3% to 7761000.0 in 2022, then rose by 20.73% to 6152000.0 in 2023, then crashed by 95.29% to 12014000.0 in 2024, then soared by 52.16% to 5747000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Income from Continuing Operations are 5747000.0 (Q2 2025), 8603000.0 (Q1 2025), and 12014000.0 (Q4 2024).